Infant Bacterial Therapeutics AB (publ) - Asset Resilience Ratio

Latest as of March 2025: 92.23%

Infant Bacterial Therapeutics AB (publ) (IBT-B) has an Asset Resilience Ratio of 92.23% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does Infant Bacterial Therapeutics AB (publ) carry for a breakdown of total debt and financial obligations.

Liquid Assets

Skr191.76 Million
≈ $20.64 Million USD Cash + Short-term Investments

Total Assets

Skr207.92 Million
≈ $22.38 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2016–2024)

This chart shows how Infant Bacterial Therapeutics AB (publ)'s Asset Resilience Ratio has changed over time. See IBT-B net assets for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Infant Bacterial Therapeutics AB (publ)'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see IBT-B company net worth.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Skr191.76 Million 92.23%
Short-term Investments Skr0.00 0%
Total Liquid Assets Skr191.76 Million 92.23%

Asset Resilience Insights

  • Very High Liquidity: Infant Bacterial Therapeutics AB (publ) maintains exceptional liquid asset reserves at 92.23% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Infant Bacterial Therapeutics AB (publ) Industry Peers by Asset Resilience Ratio

Compare Infant Bacterial Therapeutics AB (publ)'s asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Aktis Oncology, Inc. Common stock
NASDAQ:AKTS
Biotechnology 23.64%
Janux Therapeutics Inc
NASDAQ:JANX
Biotechnology 91.79%
Neurotech International Ltd
AU:NTI
Biotechnology 0.22%
SynCore Biotechnology Co Ltd
TWO:4192
Biotechnology 2.58%
Uniqure NV
NASDAQ:QURE
Biotechnology 10.94%
Jazz Pharmaceuticals plc
F:J7Z
Biotechnology 6.34%
Brainstorm Cell Therapeutics Inc
NASDAQ:BCLI
Biotechnology 0.00%
Altimmune Inc
NASDAQ:ALT
Biotechnology 82.06%

Annual Asset Resilience Ratio for Infant Bacterial Therapeutics AB (publ) (2016–2024)

The table below shows the annual Asset Resilience Ratio data for Infant Bacterial Therapeutics AB (publ).

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 93.25% Skr223.39 Million
≈ $24.04 Million
Skr239.57 Million
≈ $25.78 Million
-0.41pp
2023-12-31 93.66% Skr329.06 Million
≈ $35.41 Million
Skr351.33 Million
≈ $37.81 Million
-2.40pp
2022-12-31 96.06% Skr335.84 Million
≈ $36.14 Million
Skr349.62 Million
≈ $37.62 Million
+1.38pp
2021-12-31 94.68% Skr386.75 Million
≈ $41.62 Million
Skr408.48 Million
≈ $43.96 Million
+0.65pp
2020-12-31 94.03% Skr423.44 Million
≈ $45.57 Million
Skr450.32 Million
≈ $48.46 Million
-1.51pp
2019-12-31 95.55% Skr495.19 Million
≈ $53.29 Million
Skr518.27 Million
≈ $55.77 Million
-0.69pp
2018-12-31 96.24% Skr542.17 Million
≈ $58.35 Million
Skr563.37 Million
≈ $60.63 Million
+5.81pp
2017-12-31 90.43% Skr158.27 Million
≈ $17.03 Million
Skr175.02 Million
≈ $18.84 Million
+5.25pp
2016-12-31 85.18% Skr93.79 Million
≈ $10.09 Million
Skr110.11 Million
≈ $11.85 Million
--
pp = percentage points

About Infant Bacterial Therapeutics AB (publ)

ST:IBT-B Sweden Biotechnology
Market Cap
$75.51 Million
Skr701.68 Million SEK
Market Cap Rank
#20276 Global
#360 in Sweden
Share Price
Skr53.90
Change (1 day)
-3.75%
52-Week Range
Skr43.45 - Skr81.50
All Time High
Skr266.00
About

Infant Bacterial Therapeutics AB (publ) operates as a clinical stage pharmaceutical company develops and markets drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, which is in Phase III clinical studies to prevent necrotizing enterocolitis, as well as to improve feeding tolerance in premature infants. It is also develop… Read more